Testing a radioactive lead-212 drug in solid tumors with FAP protein
Tests a lead-212 radiation drug in adults with FAP-positive solid tumors.
Plain-language title generated from the registry record
Registry title: Lead-212 PSV359 Therapy for Patients With Solid Tumors
Key facts
- Where
- Cleveland, Columbus, Dallas, Houston, Kansas City, Lexington, Los Angeles, Madison, Miami, New York, Omaha, Pittsburgh, Rochester, and St Louis, United StatesSee the 16 sites
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT06710756, who can take part
Where in United States
- Cleveland ClinicCleveland, United StatesTaking people
- Ohio State UniversityColumbus, United StatesTaking people
- UT Southwestern University Hospital Radiology ClinicDallas, United StatesTaking people
- MD Anderson Cancer CenterHouston, United StatesTaking people
- University of KansasKansas City, United StatesTaking people
- University of KentuckyLexington, United StatesTaking people
- UCLA Department of Medicine - Hematology/OncologyLos Angeles, United StatesTaking people
- VA Greater Los Angeles Healthcare SystemLos Angeles, United StatesTaking people
- University of WisconsinMadison, United StatesTaking people
- BiogenixMiami, United StatesTaking people
- University of MiamiMiami, United StatesTaking people
- Memorial Sloan Kettering Cancer Center - Main CampusNew York, United StatesTaking people
- Nebraska Cancer SpecialistsOmaha, United StatesTaking people
- University of Pittsburgh Medical CenterPittsburgh, United StatesTaking people
- Mayo Clinic in Rochester, MinnesotaRochester, United StatesTaking people
- Saint Louis UniversitySt Louis, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Perspective Therapeutics
- Trial code
- NCT06710756
- Record updated
- 28 October 2026
- Original description
Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.Read full original descriptionShow less
A Phase I/IIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in Patients With Solid Tumors That Are Known to be Fibroblast Activation Protein (FAP)-Positive
Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Inclusion: Aged ≥ 18 years; Satisfactory organ function as determined by laboratory testing; Eastern Cooperative Oncology Group performance (ECOG) status of 0 to 1; Life expectancy > 3 months; Progressive disease despite standard therapy or for whom no standard therapy exists; Positive [203Pb]Pb-PSV359 SPECT/CT scan showing uptake of [203Pb]Pb-PSV359 in at least 1 known lesion on the 1-hour SPECT/ CT scan; Histological, pathological, and/or cytological confirmation of solid tumor malignancy that is locally advanced or metastatic.
Exclusion: Known active or uncontrolled infections requiring ongoing antifungals or antibiotics in the 3 days prior to enrollment; Existence of any medical or social issues likely to interfere with study conductor that may cause increased risk to the subject or to others, e.g., lack of ability to follow radiation safety precautions; Medical history of a condition resulting in a severe allergic reaction such as anaphylaxis or angioedema to known components of the investigational product or excipients; Major surgery within 21 days prior to the administration of [212Pb]Pb-PSV359; the subject must be sufficiently recovered and stable before treatment administration; Diagnosis of deep vein thrombosis or pulmonary embolism within 4 weeks prior to enrollment into the study; Current abuse of alcohol or illicit drugs; Treatment with any live/attenuated vaccine in the 7 days prior to enrollment; Previous treatment with any systemic anticancer therapy within 4 weeks prior to treatment on study; Known hypersensitivity to the active agent or any of the excipients; Active secondary malignancy; Known medical condition which would make this protocol unreasonably hazardous for the patient; Pregnancy or breastfeeding a child; Known brain metastases.